Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cryo Cell International (CCEL) Research & Development (2016 - 2025)

Cryo Cell International (CCEL) has disclosed Research & Development for 15 consecutive years, with $84784.0 as the latest value for Q4 2025.

  • On a quarterly basis, Research & Development fell 72.17% to $84784.0 in Q4 2025 year-over-year; TTM through Nov 2025 was $376263.0, a 69.72% decrease, with the full-year FY2025 number at $376263.0, down 69.72% from a year prior.
  • Research & Development was $84784.0 for Q4 2025 at Cryo Cell International, up from $61625.0 in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $502889.0 in Q1 2024 to a low of $3237.0 in Q2 2021.
  • A 5-year average of $161245.7 and a median of $91463.5 in 2025 define the central range for Research & Development.
  • Peak YoY movement for Research & Development: skyrocketed 2399.1% in 2022, then plummeted 80.48% in 2025.
  • Cryo Cell International's Research & Development stood at $30439.0 in 2021, then skyrocketed by 151.0% to $76401.0 in 2022, then soared by 480.89% to $443808.0 in 2023, then tumbled by 31.36% to $304629.0 in 2024, then plummeted by 72.17% to $84784.0 in 2025.
  • Per Business Quant, the three most recent readings for CCEL's Research & Development are $84784.0 (Q4 2025), $61625.0 (Q3 2025), and $131711.0 (Q2 2025).